The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental new drug application (sNDA) ...

SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first commercial European launch of MYQORZO® ...

US FDA accepts for priority review Bristol Myers Squibb’s sNDA for Camzyos to treat adolescents with symptomatic obstructive hypertrophic cardiomyopathy: Princeton, New Jersey T ...

Bristol Myers Squibb has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Camzyos heart drug for adolescents with symptomatic obstructive ...

Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the best momentum stocks to buy according to analysts. Citi initiated ...

The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in ...

Notifiable conditions are medical issues that could affect your ability to drive safely. These can include sleep apnoea, ...

(Feature Impact) Living with obstructive or non-obstructive hypertrophic cardiomyopathy (HCM) can affect everyday life, your ...

From next-generation medications to groundbreaking gene therapies and nonsurgical procedures, explore the pipeline of treatments currently being tested for oHCM.

There’s no cure for obstructive hypertrophic cardiomyopathy (oHCM) — treatments focus on symptom management and preventing complications. But the landscape is changing, and more cutting-edge therapies ...

Obstructive hypertrophic cardiomyopathy (oHCM) is a progressive condition that can worsen over time. So at some point, you might need to make adjustments to your treatment plan to keep your symptoms ...